Metastatic melanoma therapeutics market

Metastatic Melanoma Therapeutics Market, by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, and Surgery), by Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), by End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Aug 2021
CMI4608
168 Pages
Excel & Pdf
Pharmaceutical

Summary

Melanoma is a kind of skin cancer that starts from melanocytes, which are pigment cells. It is produced by excessive Ultraviolet (UV) light exposure, which causes sunburn, especially at high elevations. Melanoma is categorized into three types: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in the treatment and increase survival rates. Melanoma is getting increasingly common and has spread to other parts of the body, according to the American Academy of Dermatology. Treatment becomes much more difficult as it spreads to other sections of the body. The rare genetic conditions such as xeroderma pigmentosum also increase the risk of melanoma and it is diagnosed with the biopsy of any skin lesion.

The global metastatic melanoma therapeutics market is estimated to be US$ 6,432.3 million in 2021 and is expected to reach US$ 13,828.9 million by 2028, at a CAGR of 11.6% during the forecast period (2021 –2028).

Figure1. Global Metastatic Melanoma Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2017 - 2028

Development of new biologics is expected to drive the market growth over the forecast period.

The key players in the U.S., Europe, and Asia Pacific are focusing on the development of new biologics for the treatment of melanoma. For instance, in March 2017, Take a Novel Challenge for Drug Discovery (TaNeDS) was introduced by Daiichi Sankyo Company Limited, as a collaborative project aimed at facilitating new drug development through collaborations. In addition, it has a strategic research partnership with AgonOX, Inc. to explore innovative immunotherapy medications for the immuno-oncology market.

Metastatic Melanoma Therapeutics Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 6,432.3 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	11.6%	2028 Value Projection:	US$ 13,828.9 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Therapy: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery By Stages: Stage 0, Stage I, Stage II, Stage III, Stage IV By End User: Hospitals, Specialty Clinics, Home Healthcare, Others
Companies covered:	Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences., AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.
Growth Drivers:	Development of new biologics Rising incidence of melanoma cases Technological advancements in treatment of metastatic melanoma
Restraints & Challenges:	Lack of awareness in some developing regions High cost associated with the therapy

Global Metastatic Melanoma Therapeutics Market – Regional Analysis:

North America holds a dominant share of the market owing to the rising incidence of melanoma and other skin cancers cases in the region. For instance, according to the Skin Cancer Foundation, skin cancer affects one out of every five Americans at some point in their lives. Furthermore, the American Cancer Society recorded 91,270 new instances of melanoma in the U.S. alone in 2018. These figures emphasize the need for new medications to aid in the treatment of melanoma in the coming years.

The U.S. government's favorable reimbursement policies aided in the development of treatment options for melanoma illnesses in an attempt to meet unmet patient requirements. This is expected to give the North American market a solid foundation for expansion. Furthermore, the presence of numerous new players is expected to drive the overall market.

Figure 2. Global Metastatic Melanoma Therapeutics Market Share (%), by End User, 2021

Global Metastatic Melanoma Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 02, 2021, are approximately 198,234,951 with around 4,227,359 deaths. Moreover, Coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the metastatic melanoma therapeutics businesses of various companies as COVID-19 pandemic has led to unprecedented lockdown in several countries, globally. This lockdown has resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the products. Thus, COVID-19 pandemic has affected the economy by directly affecting the production and demand, by creating disruptions in distribution channels and also by its financial impact on firms and financial markets.

Global Metastatic Melanoma Therapeutics Market: Restraint

The major factors that hinder growth of the Global Metastatic Melanoma Therapeutics Market include lack of awareness in some developing regions and high cost associated with the therapy. For instance, according to a report in the Journal of the National Cancer Institute, the cost of melanoma treatment was approximately US$ 2.36 billion in 2010 which increased to US$ 3.16 billion in 2020.

Key Players

Major players operating in the Global Metastatic Melanoma Therapeutics Market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences, AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.

Table of Content

*Browse 35 market data tables and 36 figures on "Global Metastatic Melanoma Therapeutics Market” - Global forecast to 2028

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

The global metastatic melanoma therapeutics market size is estimated to be valued at US$ 6432.3 million in 2021 and is expected to exhibit a CAGR of 11.6% between 2021 and 2028.

What are the major factors driving the market growth?

Development of new biologics, rising incidence of melanoma cases, and technological advancements in treatment of metastatic melanoma are fuelling the growth of market.

Which is the leading therapy segment in the market?

The immunotherapy segment is the leading therapy segment in the market.

What are the key factors hampering growth of the market?

Lack of awareness in some developing regions and high cost associated with the therapy are the major factors restraining growth of the market.

Which are the major players operating in the market?

Major players operating in the market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences, AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.